HIK.L • LSE
Unlock comprehensive alternative data signals to make better investment decisions

Track website visits, page views, unique visitors, and engagement metrics over time to gauge online interest and brand strength.

Monitor Twitter follower growth, engagement rates, and social media presence to understand brand reach and community sentiment.

Analyze TikTok follower trends and viral content performance to measure youth demographic appeal and cultural relevance.

Track Facebook page likes, comments, shares, and post engagement to assess community interaction and brand loyalty.

Monitor Instagram follower growth, engagement rates, and visual content performance across demographics.

Track YouTube channel growth, video views, and subscriber engagement to measure content marketing effectiveness.

Monitor LinkedIn company page followers and professional network growth to assess B2B brand strength and talent attraction.

Track open job positions and hiring trends as a leading indicator of company expansion, contraction, or strategic shifts.

Monitor employee headcount changes on LinkedIn to gauge organizational growth, restructuring, or cost-cutting measures.

Analyze sentiment scores from Reddit discussions to understand retail investor mood and potential price momentum.

Track daily news mentions across major publications to measure media attention, PR effectiveness, and market awareness.

View key financial metrics including Revenue, Net Income, EPS, Free Cash Flow, EBITDA, and Total Assets. Access 2-year quarterly charts for Revenue & Income and Free Cash Flow trends.

Analyze technical indicators including 50-day Simple Moving Average (SMA) with price overlay and Relative Strength Index (RSI) charts.
TrendEdge provides tools and data for research and educational purposes only and does not provide investment advice or personal recommendations.
You don't hold HIK.L in your mock portfolio yet.
With a PE ratio of 13.38 and EPS of 1.22, Hikma appears reasonably valued relative to typical pharma peers, suggesting neither clear undervaluation nor overvaluation based solely on these metrics. The valuation implies the market expects steady, but not explosive, earnings growth and sees the business as fundamentally profitable. However, without multi‑year revenue and margin data, the strength and durability of growth and profitability are not fully verifiable from the provided information.
The stock trades at $1.6K, below its 200-day moving average of $1.8K, indicating it is in a longer-term downtrend despite a 5.3% gain over the last month. The RSI at 36.96 is near, but not yet in, oversold territory, suggesting lingering selling pressure and weak momentum. Overall, the technical setup points to a cautious, slightly bearish outlook until the price can reclaim and sustain levels above the 200-day moving average.
Alternative data signals are broadly constructive: job openings are up 34.9% month over month to 112, which often reflects expansion plans or increased demand. Web traffic at ~181K monthly visitors and steadily growing social media followings, particularly on YouTube and LinkedIn, suggest rising engagement and brand visibility among customers, professionals, and potential recruits. These indicators collectively point to operational growth and strengthening corporate presence, which are supportive for the medium-term equity story.
Overall sentiment on Hikma Pharmaceuticals PLC is neutral, with a constructive operational backdrop offset by weak technicals. The business appears reasonably valued and profitable, and alternative data—especially hiring growth and expanding digital presence—leans supportive for future fundamentals. However, the share price trading below its 200-day moving average and a subdued RSI keep the near-term technical picture cautious, warranting patience for clearer trend confirmation.
Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals.
Key moves vs recent baseline (last day / last week)
Plain-English summary of the biggest drivers (informational)
Potential risk factors to review
Based on earnings timing, volatility, liquidity and crowd activity. Informational signals only — not investment advice.
Reassess your thesis if any of these occur: